Nevro Reports Improved Q4 Results Amid Acquisition, Outperforms Analyst Expectations Nevro’s latest quarterly report revealed a loss per share of $0.64, beating analyst estimates, and revenue of $105.55 million, surpassing forecasts. Despite ongoing acquisition by Globus Medical, Nevro’s performance in Q4 2024 showed resilience, although the company continues to operate at a loss and faces ongoing industry headwinds.456